Perrigo Reports Record Sales, Earnings and Cash Flow From Operations for F...( as well as the Company's subsequent fil...),Health

Date:8/18/2009

, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

                             PERRIGO COMPANY
                    CONSOLIDATED STATEMENTS OF INCOME
                (in thousands, except per share amounts)


                                             Fiscal Year
                                      2009        2008        2007
                                      ----        ----        ----

    Net sales                    $2,006,862  $1,729,921  $1,368,351
    Cost of sales                 1,410,865   1,212,193   1,001,167
                                  ---------   ---------   ---------
    Gross profit                    595,997     517,728     367,184
                                    -------     -------     -------

    Operating expenses
       Distribution                  24,203      25,152      23,478
       Research and development      77,922      72,191      66,480
       Selling and
        administration              231,639     220,429     170,124
                                    -------     -------     -------
          Subtotal                  333,764     317,772     260,082
                                    -------     -------     -------
       Write-off of in-process
         research and
         development                    279       2,786       8,252
       Restructuring                 14,647       2,312         879
                               
'/>"/>
SOURCE  Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 
Related medicine news :

1. Perrigo Company Announces Quarterly Dividend
2. Perrigo Company Will Release Fiscal Year 2009 Results on August 18, 2009
3. Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ
4. Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges
5. Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB
6. Perrigo Reports Record Third Quarter
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
9. Perrigo Begins Shipments of Ibuprofen PM
10. Perrigo Reports Record Second Quarter Sales
11. Perrigo Company Announces Quarterly Dividend